Whether you’re a healthcare professional, partner, investor, or media, contact our team at
The latest publications, conference presentations, expert commentary and media coverage on POLB 001, our oral p38 MAPK inhibitor targeting cancer immunotherapy-induced CRS.
Latest news
MHRA grants Clinical Trial Authorisation for POLB 001 TOPICAL Trial
Interim data expected Summer 2026
Peer-reviewed publications & conference abstracts
Publication
POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers
Frontiers in Immunology
Abstract
POLB 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS
ASH Annual Meeting 2024
Abstract
POLB 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome (CRS)
ASH Annual Meeting 2023
KOL perspectives
“Bispecific antibodies will only be delivered in specialist cancer centres until there is a way to make treatment safe enough to extend them to a much wider patient population.”
Prof. Gareth Morgan, US Consultant Haematology, Perlmutter Cancer Center, NYU Langone.
“If there was a therapy that was orally delivered, a whole lot of infrastructure requirement falls away.”
Prof. Martin Kaiser, Consultant Haemato-Oncologist, Institute of Cancer Research & Royal Marsden Hospital
“I have seen first-hand the challenges that CRS presents to the delivery of cancer immunotherapies, requiring many of our patients to be hospitalised for treatment. These transformative therapies will continue to be restricted until there is a way to administer them more safely. POLB 001 holds great promise in tackling this issue; potentially leading to improved patient wellbeing, reducing the strain on healthcare systems while making these treatments more accessible to a broader patient population.”
Emma Searle MBChB MA MRCP FRCPath PhD
Consultant Haematologist at The Christie NHS Foundation Trust & Chief Investigator, TOPICAL trial
Thought leadership
Thought leadership
Role of supportive care in the future of cell therapies
An expert perspective exploring how supportive care, including CRS prevention, will shape the future delivery of cell and gene therapies, and the role of agents like POLB 001 in enabling broader patient access beyond specialist centres.
Cell and Gene Therapy Insights
Thought Leadership
A breakthrough Era for Cancer Drugs – but are they reaching enough patients?
Liam Tremble outlined that targeted and advanced therapies, among others, have pushed oncology treatments forward. But how can medical staff make sure all patients are included?
European Biopharmaceutical Review
Podcasts & interviews
video Interview
ESMO25: Transforming the cancer immunotherapy field, with Poolbeg’s Liam Tremble
POLB 001 clinical trial, which aims to investigate its safety and efficacy, in particular its ability to reduce the incidence of CRS, in ~ 30 relapsed/refractory multiple myeloma patients receiving an approved bispecific antibody.
Pharmaphorum
podcast
Stand Up to Cancer Day
Poolbeg features in this Stand Up to Cancer Day episode exploring the science behind POLB 001 and the challenge of making cancer immunotherapies safer and more accessible.
Deep Tech Digest · Base to Base Biotech
Podcast
Poolbeg CEO on the biotech’s big bet on small molecules
Jeremy Skillington joins the In Vivo podcast to discuss why Poolbeg is backing small molecules to solve some of the biggest challenges in oncology, including the CRS bottleneck limiting bispecific antibody rollout.
In Vivo Podcast · Citeline
VIDEO INTERVIEW
In conversation: Luke O’Neill & Jeremy Skillington ask ‘Can Ireland become a Pharma Powerhouse’
Luke O’Neill, professor of biochemistry in the School of Biochemistry & Immunology at Trinity College Dublin, and Jeremy Skillington, CEO of Poolbeg
Business Plus